|Bid||81.45 x 800|
|Ask||81.45 x 1400|
|Day's range||81.02 - 83.50|
|52-week range||75.77 - 100.62|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||28.89|
|Earnings date||25 May 2023|
|Forward dividend & yield||2.76 (3.39%)|
|Ex-dividend date||22 Jun 2023|
|1y target est||91.41|
There was plenty of action in the company's shares in the wake of its divisive fourth-quarter results.
Medtronic's (MDT) latest acquisition will increase its capacity to assist more individuals with diabetes worldwide within a single, seamless Medtronic support ecosystem.
Joining me are Geoff Martha, Medtronic chairman and chief executive officer; and Karen Parkhill, Medtronic chief financial officer. Geoff and Karen will provide comments on the results of our fourth quarter and fiscal year 2023, which ended on April 28, 2023, and our outlook for fiscal year '24.
Strong growth in the Cardiovascular, Medical Surgical, and Neuroscience portfolios, and in Diabetes markets drove Medtronic (MDT) Q4 revenues.
Shares of the medical device maker Medtronic (NYSE: MDT) were down by 5% on heavy volume as of 10:53 a.m. ET Thursday. Although Medtronic topped Wall Street's consensus forecasts for the three-month period, investors appear to be reacting negatively to the company's financial guidance. Management blamed a stubbornly strong dollar and persistently high inflation for this softer-than-expected financial guidance.
Yahoo Finance Live discusses a drop in shares of Medtronic after the medical device maker issued a weaker than expected forecast.
The headline numbers for Medtronic (MDT) give insight into how the company performed in the quarter ended April 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Medtronic (MDT) delivered earnings and revenue surprises of 0.64% and 3.59%, respectively, for the quarter ended April 2023. Do the numbers hold clues to what lies ahead for the stock?
(Reuters) -Medtronic Plc on Thursday forecast annual profit below Wall Street estimates, as a strong U.S. dollar and persistently high costs of raw goods weighed on the medical device maker's earnings, sending its shares down more than 4% in early trading. The company warned in February that rising raw material prices and high wages due to stubbornly high inflation would continue to impact its full-year profit. Medtronic forecast profit of $5 per share to $5.10 per share for the fiscal year 2024, below analysts' estimates of $5.20 per share, according to Refinitiv.
Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness.
Medtronic (NYSE: MDT) is on a roll. Its shares have soared close to 15% year to date, easily outperforming the S&P 500. But is Medtronic a stock to consider buying right now? Here are the bull and bear cases for the medical device giant.
Medtronic (NYSE: MDT) and Johnson & Johnson (NYSE: JNJ) are perfect examples of this type of winning long-term investment. Medtronic sells devices worldwide related to diabetes, cardiovascular, neuroscience, and surgery. Thanks to its vast portfolio, Medtronic has increased earnings over time.
Medtronic (MDT) is likely to have prioritized its R&D investments, which might get reflected in the fiscal Q4 results.
Investors who focus on long-term opportunities in the stock market look for well-established companies that are already profitable and have a track record of revenue growth. Two wildly different healthcare companies that both fit that description are Vertex Pharmaceuticals (NASDAQ: VRTX) and Medtronic (NYSE: MDT). Vertex, a biopharmaceutical company founded in 1989, has improved annual revenue by 636% over the past decade.
Within cardiac rhythm management, Medtronic's (MDT) pacing business continues to outperform the market, banking on strong global growth of its Micra leadless pacemaker family.
Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the latest trading session, Medtronic (MDT) closed at $89.31, marking a +0.48% move from the previous day.
Stryker (NYSE: SYK) and Medtronic (NYSE: MDT) are a pair of the biggest and most important medical-device and supply companies out there, but they're a bit different in the stability of the dividend income they offer to investors. Overall, Stryker's business is quite stable: It makes medical equipment, medical instruments, and surgical robotics for healthcare systems worldwide, and there isn't much in the way of rapidly shifting demand for its major segments. But it can reliably generate growth by investing in research and development (R&D) to make incremental improvements to its existing products, even if that growth is unlikely to be rapid due to the slow-growing nature of its markets. For example, developing more-advanced hip replacement products for use with its surgical robot system probably won't make investors rich overnight, but it'll keep the top and bottom lines expanding.
Medtronic (NYSE: MDT) is a massive business that's changing rapidly now to keep up with shifts in its markets and an evolving global economy -- all of which can make it a bit difficult for observers to understand it as an investment. Let's dive in and take a peek at three factors that smart investors appreciate about Medtronic so you'll be better prepared when it comes to your decision to buy, sell, or hold. Per Medtronic's management, there's a massive transformation underway that's set to reshape the business and make it run more efficiently across a bevy of metrics.
Medtronic (NYSE: MDT), based in Dublin, Ireland, is a well-known player in the medical device industry. Its business has been stable despite the economic downturns, which is evident from the steady growth in revenue and earnings over the last few years. Medtronic has also made a name for itself by hiking its dividend for 45 consecutive years.
Key Insights Institutions' substantial holdings in Medtronic implies that they have significant influence over the...
Medtronic (NYSE: MDT) is on a roll in more than one way. The medical device giant is beating the S&P 500 since the start of 2023. At the same time, Medtronic has grown its dividend over time, making it a top dividend stock to own.
Healthcare stocks always make a great addition to long-term portfolios. Most of us know Pfizer (NYSE: PFE) well for one particular product -- the COVID-19 vaccine. After all, the company dominates the market and has brought in billions of dollars in revenue from the vaccine over the past two years.
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Medtronic (NYSE: MDT) investors don't have reason to sweat today, but they might want to start thinking about whether the company can sustain its dividend payments in the long run. Thanks to a handful of headwinds and chronically slow growth, it's possible that this colossus is starting to overextend itself. The first thing investors need to know about Medtronic and its chances of continuing to pay its dividend is that it's an absolutely gargantuan medical device manufacturer that makes a mind-boggling number of products distributed globally.